Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colonic Neoplasms 2Neurologic Manifestations 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Attention Deficit Disorder with Hyperactivity 1

Interventions

lutetium Lu 177 dotatate 5Data Collection 3telotristat ethyl 2Somatostatin 2Positron-Emission Tomography 2Magnetic Resonance Spectroscopy 2Everolimus 2Drug Therapy 2Biopsy 2surufatinib 1lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neuroendocrine Tumors × Cytidine Triphosphate × Clear all
NCT01163526 2017-01-30

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Stanford University

Terminated
13 enrolled
EndocrineGastrointestinalNET

Colonic Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Neurologic Manifestations, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡